文献速递冠心病血脂与心血管预防

COVID-19合并急性冠脉综合征的国际前瞻性注册研究

International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

该国际多中心前瞻性注册研究纳入55个中心2020年3月至7月因疑似ACS行侵入性冠脉造影的COVID-19阳性患者,比较其与疫情前国家数据库的临床特征和院内结局。结果显示COVID-ACS患者症状至入院时间显著延长,院内死亡率显著高于对照,心源性休克发生率更高,是STEMI患者预后更差的主要贡献因素。

要点

  • COVID-19合并ACS患者症状至入院时间显著长于疫情前对照。
  • COVID-STEMI和NSTE-ACS患者院内死亡率均显著高于疫情前对照。
  • COVID-STEMI患者心源性休克发生率显著高于对照,是预后差的主因。

核心结论

  • COVID-19阳性ACS患者就诊延迟,院内死亡率较疫情前ACS人群显著增高。
  • 心源性休克发生率高及其死亡率高是COVID-19阳性STEMI患者预后更差的主要贡献因素。

研究设计与样本

  • 国际前瞻性COVID-ACS注册研究,55个中心,2020年3月1日至7月31日纳入因疑似ACS行侵入性冠脉造影的COVID-19阳性或高度临床疑似患者。
  • 共纳入144例STEMI和121例NSTE-ACS患者,结果与英国MINAP 2019和BCIS 2018-2019国家数据库比较。

主要发现

  • 症状至入院时间:COVID-STEMI vs BCIS中位数339.0 min vs 173.0 min(p<0.001);COVID NSTE-ACS vs MINAP 417.0 min vs 295.0 min(p=0.012)。
  • 院内死亡率:COVID-STEMI 22.9% vs 5.7%(p<0.001);COVID NSTE-ACS 6.6% vs 1.2%(p<0.001)。
  • 多变量倾向分析调整合并症后,STEMI亚组比值比3.33(95%CI 2.04-5.42)。
  • 心源性休克:COVID-STEMI 20.1% vs BCIS 8.7%(p<0.001)。

临床怎么用

  • 对COVID-19合并ACS患者应警惕就诊延迟和院内死亡风险增高。
  • 对COVID-19阳性STEMI患者需重点关注心源性休克的发生与救治。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Published data suggest worse outcomes in acute coronary syndrome (ACS) patients and concurrent coronavirus disease 2019 (COVID-19) infection. Mechanisms remain unclear. OBJECTIVES: The purpose of this study was to report the demographics, angiographic findings, and in-hospital outcomes of COVID-19 ACS patients and compare these with pre-COVID-19 cohorts. METHODS: From March 1, 2020 to July 31, 2020, data from 55 international centers were entered into a prospective, COVID-ACS Registry. Patients were COVID-19 positive (or had a high index of clinical suspicion) and underwent invasive coronary angiography for suspected ACS. Outcomes were in-hospital major cardiovascular events (all-cause mortality, re-myocardial infarction, heart failure, stroke, unplanned revascularization, or stent thrombosis). Results were compared with national pre-COVID-19 databases (MINAP [Myocardial Ischaemia National Audit Project] 2019 and BCIS [British Cardiovascular Intervention Society] 2018 to 2019). RESULTS: In 144 ST-segment elevation myocardial infarction (STEMI) and 121 non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients, symptom-to-admission times were significantly prolonged (COVID-STEMI vs. BCIS: median 339.0 min vs. 173.0 min; p < 0.001; COVID NSTE-ACS vs. MINAP: 417.0 min vs. 295.0 min; p = 0.012). Mortality in COVID-ACS patients was significantly higher than BCIS/MINAP control subjects in both subgroups (COVID-STEMI: 22.9% vs. 5.7%; p < 0.001; COVID NSTE-ACS: 6.6% vs. 1.2%; p < 0.001), which remained following multivariate propensity analysis adjusting for comorbidities (STEMI subgroup odds ratio: 3.33 [95% confidence interval: 2.04 to 5.42]). Cardiogenic shock occurred in 20.1% of COVID-STEMI patients versus 8.7% of BCIS patients (p < 0.001). CONCLUSIONS: In this multicenter international registry, COVID-19-positive ACS patients presented later and had increased in-hospital mortality compared with a pre-COVID-19 ACS population. Excessive rates of and mortality from cardiogenic shock were major contributors to the worse outcomes in COVID-19 positive STEMI patients.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kite TA, Ludman PF, Gale CP, et al. International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19. J Am Coll Cardiol. 2021. PMID: 34016259. doi:10.1016/j.jacc.2021.03.309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。